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Human alpha and beta defensins contribute substantially to innate immune defenses against microbial and viral
infections. Certain nonhuman primates also produce theta-defensins—18 residue cyclic peptides that act as HIV-1
entry inhibitors. Multiple human theta-defensin genes exist, but they harbor a premature termination codon that
blocks translation. Consequently, the theta-defensins (retrocyclins) encoded within the human genome are not
expressed as peptides. In vivo production of theta-defensins in rhesus macaques involves the post-translational
ligation of two nonapeptides, each derived from a 12-residue ‘‘demidefensin’’ precursor. Neither the mechanism of this
unique process nor its existence in human cells is known. To ascertain if human cells retained the ability to process
demidefensins, we transfected human promyelocytic cells with plasmids containing repaired retrocyclin-like genes.
The expected peptides were isolated, their sequences were verified by mass spectrometric analyses, and their anti-
HIV-1 activity was confirmed in vitro. Our study reveals for the first time, to our knowledge, that human cells have the
ability to make cyclic theta-defensins. Given this evidence that human cells could make theta-defensins, we attempted
to restore endogenous expression of retrocyclin peptides. Since human theta-defensin genes are transcribed, we used
aminoglycosides to read-through the premature termination codon found in the mRNA transcripts. This treatment
induced the production of intact, bioactive retrocyclin-1 peptide by human epithelial cells and cervicovaginal tissues.
The ability to reawaken retrocyclin genes from their 7 million years of slumber using aminoglycosides could provide a
novel way to secure enhanced resistance to HIV-1 infection.
Citation: Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, et al. (2009) Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol 7(4):
e1000095. doi:10.1371/journal.pbio.1000095
Introduction
Nearly 33 million people are infected with HIV worldwide
[1,2], and despite extensive efforts there are no effective
vaccines or other countermeasures to protect against HIV
transmission [3]. In our attempts to find effective anti-HIV
agents, our group determined that certain synthetic h-
defensins called ‘‘retrocyclins’’ are potent inhibitors of HIV-
1 infection [4–8]. Retrocyclins belong to a large family of
antimicrobial peptides known as defensins, all of which are
cationic, tri-disulfide bonded peptides that have important
roles in innate host defense. On the basis of the position of
the cysteines and the disulfide bonding pattern, defensins are
grouped into three subfamilies: a-defensins, b-defensins, and
h-defensins [9,10].
h-Defensins such as retrocyclin have a cyclic peptide
backbone, derived from the head-to-tail-ligation of two
peptides that each contributes nine amino acids to form
the 18-residue mature peptide [11]. h-Defensins are the only
known cyclic peptides in mammals and were originally
isolated from rhesus macaque leukocytes and bone marrow
[11–13]. While h-defensin peptides are produced in old world
monkeys and orangutans, in humans they exist only as
expressed pseudogenes [14]. A premature termination codon
in the signal peptide portion of human retrocyclin mRNA
prevents its translation. The retrocyclin gene is otherwise
remarkably intact, showing 89.4% identity with rhesus h-
defensins. Its genetic information was utilized to recreate
retrocyclins synthetically and confirm their activity against
both X4 and R5 strains of HIV-1 [4–7].
Retrocyclins inhibit the fusion of HIV-1 Env by selec-
tively binding to the C-terminal heptad repeat region on
gp41 blocking 6-helix bundle formation [15,16]. RC-101 is a
congener of retrocyclin with a single arginine to lysine
substitution that retains structural and functional similarity
to retrocyclin [4]. RC-101 exhibited enhanced anti-HIV-1
activity against over two dozen primary isolates from
several clades [7,8], and did not induce inflammation or
toxicity in organotypic models of human cervicovaginal
tissue [17]. Continuous passaging of HIV-1 BaL in the
presence of subinhibitory concentrations of RC-101 for 100
days induced only minimal viral resistance [18]. Given these
beneficial attributes, we envisioned that restoring the
endogenous expression of retrocyclins in humans would
provide an effective and natural way of combating HIV-1
infection.
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In the current study we restored the translation of this
evolutionarily lost retrocyclin peptide by ablating the pre-
mature termination codon using site-directed mutagenesis,
and analyzed whether human cells can synthesize biologically
active retrocyclins. We found that promyelocytic HL60 cells
stably transfected with retrocyclin constructs in which the
premature termination codon was corrected could express
retrocyclins. Application of the expressed retrocyclins to
TZM-bl cells, PM1 cells, and peripheral blood mononuclear
cells (PBMCs) conferred protection against HIV-1 infection.
Moreover, mass spectrometric techniques confirmed the
presence of correctly folded mature retrocyclin peptides.
We also explored methods to read-through the premature
termination codon within the retrocyclin pseudogene. Pre-
vious reports revealed that aminoglycoside antibiotics could
suppress the termination codon of pseudogenes and disease-
associated nonsense mutations [19–25]. In bacteria, amino-
glycosides bind strongly to the decoding site on the 16S rRNA,
thereby hindering protein synthesis [26]. However, in eukar-
yotes, aminoglycosides bind to the eukaryotic decoding site
with low affinity and induce a low level of translational
misreading, which suppresses the termination codon through
the incorporation of an amino acid in its place [27]. Herein,
we utilized aminoglycosides to induce translational read-
through of the h-defensin pseudogene, which restored the
expression of functional anti-HIV-1 retrocyclin peptides in
human cervicovaginal tissue models. Topical application of
aminoglycosides to produce endogenous retrocyclins in the
vaginal mucosa might soon be an effective preventative to
combat sexual transmission of HIV-1.
Results and Discussion
Creation of Promyelocytic Cells Stably Transfected with
Retrocyclin Constructs
h-Defensins are formed by post-translational modification
of two 12-residue gene products, each of which is processed
to give a nonapeptide that contains three cysteines. The N-
terminus of one nonapeptide forms a peptide bond with the
C-terminus of another nonapeptide, resulting in a cyclic 18
residue peptide with three intramolecular disulfide bonds
[11,14]. To determine if human cells have retained the ability
to process h-defensins, we transfected promyelocytic HL60
cells with retrocyclin constructs each encoding a nonapeptide
in which the premature termination codon was replaced with
a glutamine (17Q).
Four types of constructs were produced: R1, R3, A1, and A3
(Figure 1). Aside from the corrected premature termination
codon (17Q), all constructs were engineered to contain two
termination codons at the end of the gene to ensure read-
fidelity. Constructs with an ‘‘R’’ designation terminate after
the retrocyclin portion of the gene, while constructs with an
‘‘A’’ designation contain the retrocyclin portion with addi-
tional downstream residues that might be critical for trans-
lation and/or processing [14,28]. Constructs with a ‘‘1’’
designation do not have any additional residues mutated,
while constructs with a ‘‘3’’ designation have the additional
Arg ! Lys mutation (R70K) encoding the RC-101 non-
apeptide. HL60 cells were cotransfected by electroporation
with either R1 and R3, or A1 and A3, and propagated in the
presence of G418 (300 lg/ml) to create stably transfected cell
lines. Stable transfection was verified by analyzing genomic
DNA and mRNA (Figure S1). Since two different constructs
were cotransfected for each condition, combinatorially it
would be possible to generate three different retrocyclin
peptides as illustrated in Figure 1B. For example, if cells were
cotransfected with the R1 and R3 constructs, they could
theoretically generate a heterodimer (HL60 cells containing
retrocyclin constructs R1 and R3 [R1R3]) or homodimers
(R1R1 or R3R3).
Extracts of Promyelocytic Cells Stably Transfected with
Retrocyclin Constructs Are Active against HIV-1
We next analyzed if correcting the termination codon in
the retrocyclin constructs could restore the translation of
biologically active retrocyclin peptides. The infection of
TZM-bl cells with HIV-1 BaL was significantly reduced when
cells were treated with cellular acid extracts of R1R3 cells (p,
0.004) and HL60 cells containing retrocyclin constructs A1
and A3 (A1A3) (p , 0.002) (Figure 2A). A standard tetra-
zolium MTT assay revealed that the extracts did not affect
cellular metabolism at the concentrations used in the
experiment (Figure 2E). Addition of A1A3 cell extracts to
HIV-1 infected PM1 cells (Figure 2B) and PBMCs (Figure 2C)
showed significant (p , 0.002 and p , 0.004, respectively)
decrease in the viral titer as compared to cells treated with
control HL60 cell extract. A trypan blue exclusion assay was
performed in PBMCs to monitor cell viability (Figure 2F). We
next affinity purified R1R3 and A1A3 cell extracts using anti-
RC-101 antibody and confirmed the antiviral activity in a
luciferase-based assay system (Figure 2D). Interestingly, A1A3
cell extracts were found to be consistently more active than
equivalent amounts of R1R3 cell extract, which suggests a role
for the downstream residues in retrocyclin processing. These
results indicate that biologically active recombinant retro-
cyclin peptides can be synthesized in human promyelocytic
cells. As a next step we tested the presence of retrocyclin in
promyelocytic cells using immunostaining.
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Author Summary
Defensins are a large family of small antimicrobial peptides that
contribute to host defense against a broad spectrum of pathogens.
In primates, defensins are divided into three subfamilies—alpha,
beta, and theta—on the basis of their disulfide bonding pattern.
Theta-defensins were the most recently identified defensin sub-
family, isolated initially from white blood cells and bone marrow of
rhesus monkeys. They are the only known cyclic peptides in
mammals and act primarily by preventing viruses such as HIV-1 from
entering cells. Whereas theta-defensin genes are intact in Old World
monkeys, in humans they have a premature stop codon that
prevents their expression; they thus exist as pseudogenes. In this
work, we reveal that, upon correction of the premature termination
codon in theta-defensin pseudogenes, human myeloid cells
produce cyclic, antiviral peptides (which we have termed ‘‘retro-
cyclins’’), indicating that the cells retain the intact machinery to
make cyclic peptides. Furthermore, we exploited the ability of
aminoglycoside antibiotics to read-through the premature termi-
nation codon within retrocyclin transcripts to produce functional
peptides that are active against HIV-1. Given that the endogenous
production of retrocyclins could also be restored in human
cervicovaginal tissues, we propose that aminoglycoside-based
topical microbicides might be useful in preventing sexual trans-
mission of HIV-1.
Immunofluorescence Staining of Stably Transfected HL60
Cells Reveals Retrocyclin Peptides
Immuno-dotblot analyses revealed that our anti-RC-101
antibody specifically recognized lysine-containing human
retrocyclin analogs (synthetic RC-101 and RC-101–2K) and
RC-100 (i.e., wild-type form) to a lesser extent (Figure 3A) but
not human neutrophil peptides 1–3, or peptides with very
similar tertiary structure including rhesus theta defensin-1
(RTD-1) and protegrin-1 (PG-1) (Figure 3B). This antibody
was used to visualize the expressed retrocyclin peptides in the
stably transfected HL60 cells by immunofluorescence stain-
ing, which revealed that R1R3 cells and A1A3 cells were
brightly stained as compared to vector control (VC) cells
(Figure 3C). Slides treated with preimmune serum showed no
staining (unpublished data). Note that the staining of A1A3
was brighter than R1R3 and the morphology of A1A3 cells
was smaller than VC cells. Experiments were next designed to
purify and confirm the identity of the expressed retrocyclin
peptides from the cell extracts.
Stably Transfected Promyelocytic Cells Produce
Retrocyclin Peptides
Reverse-phase high-performance liquid chromatography
(RP-HPLC) was utilized to purify the recombinant retrocyclin
peptides from stably transfected HL60 cell extracts. Figure 4A
shows the RP-HPLC trace of A1A3 and synthetic RC-101.
Synthetic RC-101 was recovered in fractions collected at 26–
28 min. A1A3 HPLC Fractions collected from 23–30 min were
analyzed on a 16% Tricine-SDS-gel. Control samples did not
contain any protein bands at the expected size, whereas
fractions from R1R3 cell extracts revealed protein bands of
about 6-kDa size (unpublished data). Interestingly, A1A3
HPLC fractions revealed multiple protein bands, which we
further analyzed by western blot (Figure 4B). The western blot
analysis revealed bands at sizes corresponding to a monomer,
dimer, and trimer of retrocyclin. Interestingly, the presence
of multimeric forms of retrocyclin has been independently
observed by Daly and colleagues [29]. Furthermore, the RP-
HPLC purified A1A3 fractions inhibited entry of HIV-1 BaL
in TZM-bl cells (Figure 4C). The IC50 of retrocyclin peptides
expressed by A1A3 cells (2 lg/ml) was similar to that of
synthetic RC-101 (1.25 lg/ml) [8].
To determine the identity of the retrocyclin peptide
expressed by A1A3 cells, HPLC fraction 26 was analyzed by
mass spectrometric analysis (MALDI-TOF-MS) at the Micro-
chemical and Proteomics Facility, Emory University (Atlanta,
Georgia, US). Analysis of A1A3 Fraction 26 revealed peaks
with masses 1,889.775 Da (oxidized) and 1895.890 Da
(reduced), which is nearly identical to the expected mass of
synthetic cyclic RC-101 (1,889.85 Da and 1,895.96 Da,
respectively; unpublished data) and is in agreement with
reduction of the three disulfide bridges in the molecule.
Furthermore, treatment with iodoacetamide yielded mass
species of 2,238.081 Da for the A1A3 fraction 26 and
Figure 1. Design of Retrocyclin Constructs
(A) Shows a schematic of the four constructs (R1, R3, A1, and A3) used for stable transfections along with native retrocyclin cDNA. All constructs have
two termination codons at the end to ensure read-fidelity (red). Constructs A1 and A3 contain additional downstream residues (orange), whereas
constructs R1 and R3 lack them. The two arrows indicate the position at which the two site-directed mutagenesis (17Q and R70K) were performed.
(B) Shows the three possible mature retrocyclin peptides that could be formed from the constructs, homodimers of R1 or A1 encoding RC-100 (wild-
type retrocyclin), heterodimers of A1 and A3 or R1 and R3 encoding RC-101 (single lysine congener), and homodimers of R3 or A3 encoding RC-101–2K
(double lysine congener).
doi:10.1371/journal.pbio.1000095.g001
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2,238.071 Da for RC-101 corresponding to the predicted 6-
fold–alkylated form of RC-101 (expected mass ¼ 2,238.097
Da). Comparison of spectrum of the Lys-C digest of reduced/
alkylated synthetic RC-101–2K (peak at 1,123.577 Da; peptide
cleaved at two Lys-Gly bonds; Figure 4D), synthetic RC-101
(peak at 2,256.097 Da; peptide cleaved at a single Lys-Gly
bond; N-terminal sequence determined as: Gly-Ile-Cys-Arg-;
Figure 4E), and A1A3 fraction 26 (peak at 2,256.010 Da)
suggests that the A1A3 cells are expressing RC-101 (Figure
4F). These data confirmed that correctly folded mature
retrocyclin peptides can be expressed by human cells. In
the following experiments we explored alternative methods
to express the peptide endogenously. Of particular interest
was the effect of aminoglycosides in mediating varying
degrees of termination codon read-through as previously
described [19–25].
Aminoglycosides Mediate Read-Through of Termination
Codon of Retrocyclin Gene and Restore Anti-HIV-1 Activity
We tested the ability of three commonly used aminoglyco-
sides (gentamicin, amikacin, and tobramycin) to induce
termination codon read-through of retrocyclin cDNA. The
native retrocyclin gene was fused with a luciferase reporter at
the C terminus to create two constructs: unrescued RC-101
and rescued RC-101 (positive control) as shown in Figure 5A.
These constructs were transfected into HOS-CD4-CCR5 cells,
grown in the presence of varying concentrations of amino-
glycosides, and the degree of read-through quantified by
measuring luciferase. Application of tobramycin (10 lg/ml)
was the most effective, producing a 26-fold increase in read-
through (p , 0.0007; Figure 5B).
Having thus established the optimal aminoglycoside con-
centration required to achieve read-through of retrocylin
cDNA, we next determined if aminoglycosides could restore
the translation and anti-HIV-1 activity of native retrocyclin
peptides. HeLa-derived cells lines such as TZM-bl cells can
natively express retrocyclin mRNA (unpublished data). We
applied aminoglycosides to TZM-bl cells and challenged them
with HIV-1 BaL. We found that cells treated with gentamicin
and tobramycin significantly (p , 0.0005 and p , 0.0001,
respectively) inhibited HIV-1 infection as compared to
untreated cells (Figure 5C). The effect was modest when
compared to inhibition by synthetic peptides. Cell viability,
determined by a tetrazolium-based MTT assay, was not
affected by the application of aminoglycosides at the
mentioned concentrations (Figure 5E).
Figure 2. Extracts from HL60 Cells Stably Transfected with Retrocyclin Constructs Are Active against HIV-1 Infection
(A) TZM-bl cells were treated with extracts or peptide as indicated in the figure and infected with HIV-1 BaL (6.5 ng/ml p24) for 24 h. Infection was
measured as percent luciferase activity compared to cells treated with control cell extract (average relative luciferase units [RLUs] of control HL60 extract
¼ 178,200).
(B, C) PM1 cells and PBMCs were treated with extracts or peptide as indicated and infected with HIV-1 BaL (2 ng/ml p24) and cultured for 5–9 d. Bars
represent percent BaL HIV-1 levels in the supernatants collected on days 5 (B) and 9 (C). The amount of p24 in PM1 cells treated with control extract¼
76.85 ng/ml and in PBMCs treated with control extracts ¼ 55.99 ng/ml.
(D) TZM-bl cells were treated with immunopurified (IP) extracts or peptides as indicated and infected with BaL HIV-1 (p24¼ 2 ng/ml) for 24 h. Infection
was quantified as percent luciferase activity compared to cells treated with control HL60 cell IP extracts (average RLU¼ 764,460). Error bars represent
standard error of the mean (SEM). n¼ 3–4; #, p , 0.004; *, p , 0.002; **, p ,0.0005.
(E) Cellular viability of TZM-bl cells treated with HL60 acid extracts as indicated was determined by measuring the reduction of MTT after 24h (n¼ 3).
Bars represent percent viability as compared to vehicle control and error bars represent SEM.
(F) Cell death was monitored in PBMCs treated with the acid extracts by a trypan blue exclusion assay on day 9 (n¼ 1).
doi:10.1371/journal.pbio.1000095.g002
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In order to visualize the retrocyclins expressed by
application of aminoglycosides, we performed immunostain-
ing. TZM-bl cells were treated with PBS control or 10 lg/ml
tobramycin and stained with anti-retrocyclin antibody or
preimmune serum. Control cells showed no staining while
cells treated with tobramycin revealed brightly stained cells
suggesting that aminoglycosides can induce the expression of
retrocyclin peptides (Figure 5D).
We next incubated TZM-bl cells with tobramycin (10 lg/ml)
for 24 h, and then treated the cells with preimmune or anti-
retrocyclin serum followed by infection with HIV-1. Figure 5F
reveals that cells treated with preimmune serum showed a
modest yet significant reduction in infection as compared to
cells treated with anti-retrocyclin antibodies (p , 0.018),
suggesting that the antibody inhibited the endogenous
retrocyclins. These data confirm that the anti-HIV-1 activity
observed is due to the endogenous retrocyclin peptides
expressed when tobramycin was applied to cells.
Aminoglycosides Induce Production of Retrocyclin
Peptides in Cervicovaginal Tissues
We next analyzed the ability of aminoglycosides to induce
the expression of retrocyclin peptides in an organotypic
model cervicovaginal tissue. Tissues were treated apically
with tobramycin or control (PBS) for 24 h and anti-
retrocyclin immunohistochemical analysis was performed.
Interestingly, tissues treated with tobramycin alone and
stained with anti-retrocyclin antibody revealed brightly
stained cells (Figure 6A) suggesting that production of
retrocyclin peptides is induced upon application of amino-
glycosides. Lactate dehydrogenase (LDH) activity in the
medium underlying the tissues was performed to determine
tissue cytotoxicity. The LDH assay revealed that application
of 10 lg/ml tobramycin was not cytotoxic to the tissues
(Figure 6B). In addition, treatment of tobramycin did not
affect the metabolic activity adversely, which was determined
by an MTT assay performed on one tissue (unpublished data).
In order to purify endogenous retrocyclins expressed in the
tissues, we utilized RP-HPLC. Figure 6C shows an HPLC trace
of control, tobramycin-treated tissue extracts as compared to
synthetic RC-100 peptide. Synthetic RC-100 peptide was
recovered in fractions collected at 27–29 min. Corresponding
fractions from control and tobramycin-treated tissues were
analyzed by immuno-dotblot analysis using the anti-RC-101
antibody. Figure 6D shows that retrocyclin peptides were
Figure 3. Immunofluorescence Staining of Stably Transfected HL60 Cells Reveals Retrocyclin Peptides
(A) Retrocyclin peptides RC-100, RC-101, and RC-101–2K peptides (in duplicates) and (B) RC-100, RC-100b, RC-101, protegrin-1 (PG-1), rhesus theta
defensin-1 (RTD-1), and human neutrophil peptides 1–3 (HNP 1–3) were dotted (0–8 ng/4 ll dot) on a PVDF membrane and subjected to immuno-
dotblot analysis.
(C) VC, R1R3, and A1A3 (100,000 cells each) were fixed onto glass slides and incubated with rabbit anti-RC-101 antibody followed by biotinylated goat
anti-rabbit IgG secondary antibody and then stained using fluorescein isothiocyanate (FITC)-avidin. Slides were visualized using Zeiss Axiovert 200M
microscope system at 403magnification. The three rows show FITC staining, DIC, and the merged image, respectively. Scale bar represents 20 lm.
doi:10.1371/journal.pbio.1000095.g003
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recovered in fractions 27–29 min in tobramycin-treated
tissue samples but not in control tissue samples. The amount
of retrocyclin (RC-100) expressed in tobramycin-treated
cervicovaginal tissues was estimated by densitometry to be
approximately 1.6 lg/tissue. Together these studies show that
aminoglycosides are promising molecules to suppress the
premature termination codon of retrocyclin transcripts and
restore the ability of cervicovaginal tissues to protect cells
from HIV-1.
Conclusion
Identifying effective drugs to prevent HIV-1 infection and
other viral infections is essential for countering the spread of
these diseases. Exogenous (synthetic) retrocyclins exhibit full
activity in the complex environment of vaginal fluid and the
peptide is very well tolerated in organotypic human
cervicovaginal tissue models [17]. Moreover, HIV-1 evolves
little resistance during continued passaging in the presence
of the peptide [18]. For these and other reasons, retrocyclins
have emerged as potential topical microbicides to protect
against sexually transmitted HIV-1 infections.
In this study we have taken a different path towards
developing h-defensin therapeutics. The human pseudogenes
that encode the demidefensin precursors whose post-trans-
lational processing gives rise to mature retrocyclin are
expressed at the mRNA level in multiple organs, including
the spleen, bone marrow, thymus, testis, and skeletal muscle
[14], and cervicovaginal epithelia (A. M. Cole, unpublished
data). By transfecting human myeloid cells with plasmids
containing retrocyclin genes without a premature termina-
tion codon, we demonstrated that the ‘‘machinery’’ needed to
process, trim, splice, and oxidize retrocyclin precursors was
available in human myeloid cells. Two sets of expression
constructs were transfected into cells: a shorter form (R1R3)
that terminates at the end of the retrocyclin gene and a
longer form that contains (A1A3) additional 39 untranslated
residues (UTR). Interestingly, A1A3 cells expressed higher
levels of retrocyclin peptides as compared to R1R3 cells
indicating a role for additional residues in the translational
efficiency of these peptides. This was not altogether surpris-
ing as other studies have shown that the length of the 39-UTR
regulates translation efficiency [28,30]. Finally, we showed
that aminoglycoside-treated cells and cervicovaginal tissues
could produce retrocyclins endogenously by suppressing the
premature termination codon in their endogenous mRNA
transcript.
Since approximately 30% of inherited disorders may result
from premature termination codon mutations, there has
been tremendous interest and some progress in developing
and applying agents that can read-through premature UAA,
UAG, or UGA termination codons [25]. Although amino-
glycosides, as used in this study, have been most widely
investigated, exciting new agents such as PTC-124, have also
appeared [31,32]. In a sense, human retrocyclin-deficiency is
Figure 4. Stably Transfected Promyelocytic Cells Produce Retrocyclin
(A) Shows the RP-HPLC trace of A1A3 cell extract (from 108 cells) and 50 lg of synthetic RC-101.
(B) Western blot of A1A3 HPLC fractions (23–28 min) using rabbit anti-RC-101 antibody. The arrows indicate the multimeric forms of retrocyclin
observed in A1A3 fractions.
(C) TZM-bl cells were infected with HIV-1 (p24¼ 2 ng/ml) in the presence or absence of pooled A1A3 fractions (final dilution 1:6 in D10) or 2 lg/ml of
RC-101 for 24 h. Infection was quantified by luciferase measurement (average RLU of vehicle control with virus¼ 85,450).
Error bar represents SEM and n¼ 3–6; *, p , 0.0015; **, p ,0.0001. MALDI-TOF MS spectra of Lys-C digested (D) synthetic RC-101–2K, (E) synthetic RC-
101, and (F) A1A3 HPLC fraction 26 reveal that A1A3 cells produce RC-101.
doi:10.1371/journal.pbio.1000095.g004
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also an inherited disorder, albeit one with an incidence of
100%. It is caused by a premature termination codon
mutation that occurred after human lineage diverged from
the lineage we share with orangutans, lesser apes, and old
world monkeys. Since HIV-1 and other viruses that currently
infect humans have evolved in the absence of selective
pressure exerted by retrocyclins, the ability to reawaken this
ancestral molecule could be used to strengthen the innate
immune system’s ability to prevent or limit the infections
they now induce.
Materials and Methods
Maintenance of cells, tissues, and viruses. HL60 cells [33,34]
obtained from ATCC were cultured in Iscoves’s DMEM with 20%
FBS, 100 U/ml penicillin, and 100 lg/ml streptomycin (I20). TZM-bl
cells [35] stably expressing CD4, CCR5, and CXCR4, has firefly
luciferase gene under the control of HIV-1 promoter (from J. C.
Kappes, X. Wu, and Tranzyme Inc). TZM-bl, HOS-CD4-CCR5 [36,37]
(from N. R. Landau), PM1 cells [38], (from M. Reitz), and HIV-1 BaL,
an R5 tropic strain, were all procured through the National Institutes
of Health (NIH) AIDS Research and Reference Reagent program.
HIV-1 BaL viral stocks were prepared by infecting PM1 cells [18].
PBMCs were isolated from blood drawn from a healthy HIV-1
seronegative donor as per the guidelines of the institutional review
board of University of Central Florida. PBMCs were isolated using
Lymphosep (MP biomedicals LLC), and cultured in RPMI-1640
medium with 10% FBS (R10) supplemented with 50 units of IL-2
(R10-50U) and 5 lg/ml of phytohemagglutinin (PHA) for 3 d. The cells
were then resuspended in R10-50U at a density of 0.83 106 cells/ml
and grown for 5–6 d.
Cervicovaginal tissues (EpiVaginal) were obtained from MatTek
Corporation and maintained in proprietary growth medium as per
the company’s guidelines. The tissues were composed of a full-
thickness, stratified vaginal-ectocervical layer intermixed with Lan-
gehans cells and underlying lamina propria. The tissues were allowed
to grow on transwell cell culture inserts at the air-liquid interface.
Creation of retrocyclin constructs and stably transfected HL60
cells. Retrocyclin cDNA was amplified from human bone marrow
cDNA and cloned into pCRII-TOPO vector (Invitrogen). Two
mutations, Termination codon (17) ! Gln (Q17) and Arg (R70) !
Lys (K70) were introduced, either 17Q alone (RC-100) or both (RC-
Figure 5. Aminoglycosides Mediate Read-Through of the Premature Termination Codon within the Retrocyclin Gene and Promote Anti-HIV-1 Activity
(A) Shows a schematic of the luciferase fusion constructs unrescued RC-101 and rescued RC-101 along with native retrocyclin cDNA.
(B) HOS-CD4-CCR5 cells cultured in antibiotic free medium (D10) were transfected with unrescued RC-101 (negative control) or rescued RC-101
(positive control) plasmids along with phRL-CMV vector (transfection control). The next day transfected cells were treated with PBS for control cells or
aminoglycosides at the indicated concentrations and allowed to grow for 24 h. Read-through was determined by measuring luciferase levels. Data are
expressed as fold increase in luciferase expression normalized to renilla levels.
(C) TZM-bl cells grown in D10were treated for 30 min with PBS, RC-101 (2.5 lg/ml), RC-100 (2.5 lg/ml), or aminoglycosides as shown in the figure and
infected with HIV-1 BaL (2 ng/ml p24) for 24 h followed by luciferase measurement. Error bars represent SEM. n¼ 3–6; #, p , 0.007; * p , 0.0005; ** p
,0.0001.
(D) TZM-bl cells cultured on cover slips were treated with PBS (Con) or 10 lg/ml tobramycin (Tob) and then immunostained with rabbit preimmune or
antiretrocyclin serum using a biotinylated secondary antibody FITC-avidin system.
(E) Cellular cytotoxicity was assessed by performing an MTT assay on TZM-bl cells treated with indicated amount of peptide or aminoglycosides (n¼ 3).
Bars represent percent metabolic inhibition as compared to control (vehicleþ virus).
(F) TZM-bl cells, treated with either PBS, tobramycin (10 lg/ml), or RC-100 (2.5 lg/ml), were incubated with preimmune serum or antiretrocyclin serum
as indicated and infected with HIV-1 (p24 of 5 ng/ml). Data are represented as percent infection. Error bars represent SEM. n¼ 3;þ, p , 0.018 Statistical
significance was determined by two-tailed Student’s t-test.
doi:10.1371/journal.pbio.1000095.g005
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101) using Quick change site-directed mutagenesis (Stratagene) and
subcloned in-frame into the phCMV-luc-FSR vector (Genlantis) to
generate four constructs R1, R3, A1, and A3 (Figure 1A). Plasmids R1
and A1 encode RC-100 nonapeptide while R3 and A3 encode RC-101
nonapeptide. Constructs A1 and A3 have a longer insert that includes
additional downstream residues. HL60 cells (107 cells/400 ll Iscove’s
DMEM) were cotransfected with 2 lg each of linearized R1, R3 or A1,
A3, or phCMV-luc vector alone, by electroporation (exponential
decay wave mode- 280 V; 975 lF) and selected in I20 medium with 300
lg/ml G418 sulfate. Stable transfectants thus produced were named
according to the constructs used for cotransfection (R1R3, A1A3, or
VC). Presence of these constructs in the cells was verified using PCR
of genomic DNA (Figure S1A). PCR conditions used were the
following: initial denaturation at 95 8C for 3 min; 30 cycles of 95 8C
for 1 min; 58 8C for 1 min; 72 8C for 2 min; followed by a final
extension at 72 8C for 7 min. Sequences of the primers used for the
PCR reaction are listed in Table S1. RNA was extracted from 106 cells
(HL60, VC, R1R3, and A1A3) using TRIzol (Invitrogen), cleaned with
DNaseI (Ambion Inc.), and cDNA synthesized (iScript, BioRad).
Expression of recombinant genes was verified by PCR from the cDNA
and subsequent restriction digestion using HpyCH4V (New England
Biolabs) (Figure S1B and S1C).
Acid extraction and affinity purification of retrocyclin peptides.
HL60 cells (control, VC, R1R3, and A1A3) were extracted with 5%
acetic acid by vortexing for 20 min, centrifuged for 10 min at
10,000 g, supernatants were then vacuum-dried and resuspended in
0.01% acetic acid. HL60 acid extracts (equivalent of 20 3 106 cells)
were affinity purified using anti-RC-101 polyclonal antisera immobi-
lized to a Carbolink coupling gel (Pierce Biotechnology Inc.)
prepared according to the manufacturer’s instructions. Immuno-
purified samples were desalted using Sep-Pak C-18 cartridges
(Waters). The elutes were then dried and resuspended in 100 ll of
0.01% acetic acid. 100 lg of synthetic RC-101 peptide was also affinity
purified as positive control (RC-101 IP).
Luciferase-based infection assay to determine anti-HIV-1 activity.
TZM-bl cells (4,000 cells/well; 96-well plate) were infected with HIV-1
BaL (2–6.5 ng/ml of p24gag) in the presence of vehicle (0.01% acetic
acid), HL60 extracts (from 0.25 3 106 control, A1A3, or R1R3 cells),
affinity purified extracts (from 0.6253 106 control HL60, VC, R1R3,
A1A3 cells, or RC-101 IP diluted 1:32 times), or RC-101 (20 lg/ml)
(positive control) for 24 h. Treatments were then removed and the
infection was quantified by measuring luciferase using Bright-Glo
reagents (Promega) in an LMax luminometer (Molecular Devices).
Cytotoxicity and metabolic activity of cells were verified by a
tetrazolium-based MTT assay (R&D Systems) performed on identi-
cally treated cells.
Antiviral infection assay in suspension cells and HIV-1 p24gag
ELISA. Acid extracts of stably transfected HL60 cells were vacuum-
dried and resuspended in PBS. PM1 cells (105 cells) or PBMCs (106
cells) were treated with PBS (vehicle) or HL60 extracts (from 104 cells
for PM1 and 105 for PBMCs) of control cells or A1A3 cells or 10 lg/ml
of synthetic RC-101 and infected with HIV-1 BaL (2 ng of p24/ml) in
100 ll of RPMI medium with 20% FBS (R20) for 2 h. Cells were then
washed with 2 ml of R20, resuspended in fresh medium containing
the treatments, and cultured for 5–9 d. Subsequently on alternate
days culture supernatants were collected and fresh medium with the
corresponding treatments was added. Viability of the cells was
measured using trypan blue exclusion assay. Amount of HIV-1 virus
in the culture supernatants was quantified by ELISA for HIV-1 p24gag
(Perkin Elmer).
Immuno-dotblot assay. Peptides RC-100, RC-100b, RC-101, RC-
101–2K, synthetic protegrin-1 (PG-1), Rhesus theta defensin–1 (RTD-
1), and human neutrophil peptides 1–3 (HNP 1–3), or unknown
samples were dotted (4 ll dot) as indicated on a 0.22-lm
polyvinylidene fluoride (PVDF) membrane (Immobilon-P) that was
Figure 6. Expression of Retrocyclins in Cervicovaginal Tissue Model Using Aminoglycosides
(A) Cervicovaginal tissues were treated with PBS (Con) or 10 ll tobramycin (Tob) and incubated with rabbit preimmune serum or antiretrocyclin
antibody. The slides were then incubated with biotinylated goat anti-rabbit IgG secondary antibody and then stained using FITC-avidin.
(B) Cytotoxicity was determined by measuring LDH activity in media underlying the tissues treated with PBS or tobramycin as indicated. Bars represent
absorbance measured as 490 nm and error bars represent SEM; n¼ 6.
(C) HPLC trace of extracts of tissues treated with 10 lg/ml tobramycin (tissue þ Tob) and 20 lg of synthetic RC-100.
(D) RC-100 synthetic peptide (indicated amounts), HPLC fractions 27–29 of control, tobramycin-treated, and RC-100 were dotted on a PVDF membrane
and analyzed by immuno-dotblot.
doi:10.1371/journal.pbio.1000095.g006
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activated with methanol and presoaked in TBS. The membrane was
then probed with 1:1,000 rabbit anti-RC-101 antibody and developed
using Immun-star HRP reagent (BioRad) [17].
Immunostaining of stably transfected HL60 cells using anti-RC-101
antibody. HL60 cells (VC, R1R3, and A1A3) were fixed on slides
(100,000 cells/slide), immersed in 10% Formalin in PBS for 10 min,
washed (PBS for 2 min), incubated in Target retrieval solution (Dako
North America Inc.) for 20 min at 95 8C, cooled to 25 8C, washed,
blocked (2% Goat Serum, 0.1% Triton-X, 0.05% Tween-20, antibody
buffer [10 mg/ml BSA/1 mg/ml gelatin/PBS]) for 20 min, and incubated
in rabbit preimmune serum or rabbit anti-RC-101 antibody (1:5,000
in antibody buffer) overnight. Slides were washed, incubated in
biotinylated goat anti-rabbit IgG antibody (1:20,000 in 1% goat
serum/PBS for 30 min), followed by additional washing and treatment
with Fluorescein-Avidin D (Vector Laboratories Inc.; 1:500 in PBS for
30 min). Cover slips were mounted using Vectashield fluorescence
mounting medium and visualized using a Zeiss Axiovert 200M
microscope system.
Tissues for immunofluorescence staining were fixed in 4%
paraformaldehyde and slides were prepared by Mass Histology. The
slides were deparaffinized, washed with TBS, and stained with anti-
retrocyclin or preimmune serum and immunostained the same way as
cells. The slides were then visualized on a Zeiss Axiovert 200M
microscope system with 450 ms exposure time for all slides.
Separation of proteins from stably transfected HL60 extracts using
RP-HPLC. Acid extracts from control HL60 and A1A3 cells
(equivalent of 100 3 106 cells) were separated by RP-HPLC using
the Alliance HT Waters 2795 Separations Module on a C18 Column
equilibrated in solvent A (aqueous 0.1% TFA). Elution was done with
a gradient of 0%–95% solvent B (0.08% TFA in acetonitrile), for 75
min, at 1 ml/min. Collected fractions (1 ml each) were vacuum dried
and reconstituted in 100 ll of 0.01% acetic acid. Synthetic RC-101
peptide (control) was recovered from the fractions eluting at 26–28
min. A1A3 HPLC fractions (numbers 23–28) were electrophoresed on
a 16% Tricine-SDS gel and electroblotted on a 0.22 lm PVDF
membrane at 180 mA˚ for 22 min. The western blot membrane was
then processed as described [17] and developed with ChemiGlow
reagent (Alpha Innotech). A1A3 RP-HPLC fractions (27–30 min) were
pooled and the concentration was determined to be (2.13 ng/ll) by
densitometry measurements using Quantity one 1-D analysis (Bio-
Rad). A luciferase-based assay was used to verify the activity of A1A3
HPLC fractions (diluted three times in D10) against HIV-1 BaL (2 ng
p24/ml).
MatTek cervicovaginal tissues treated with PBS (control) or 10 lg/
ml tobramycin were extracted with T-PER reagent (Pierce Biotech-
nology Inc.) and separated by RP-HPLC. 20 lg of synthetic
retrocyclin (RC-100) was also separated as a positive control.
Synthetic RC-100 was eluted in fractions collected at 27–29 min.
Tissue samples eluted at 27–29 min were vacuum-dried to near
dryness and resuspended in 100 ll of 0.01% acetic acid. HPLC
fractions (27–29 min) of MatTek tissue extracts (control or
tobramycin-treated) and synthetic RC-100 were analyzed by immu-
no-dotblot analysis.
Mass spectrometric analysis. A1A3 HPLC Fraction 26, RC-101, and
RC-101–2K were reduced, alkylated, and treated with Lys-C protease
for 30 min before analyzing by mass spectrometry. In brief, 20 mM
Tris [2-carboxyethyl] phosphine (TCEP) was used to reduce (30 min at
25 8C) the samples, alkylated by incubating the samples with
iodoacetamide (60 mM; 45 min at 25 8C [pH 8–9]) followed by
digestion with Lys-C (Wako Chemicals; 30 min at 37 8C) and subjected
to MALDI-TOF-MS analysis using a model 4700 Proteomics Analyzer
(Applied Biosystems) as described previously [39]. Lys-C digested RC-
101 was desalted using C18 ZipTip (Millipore Corp.) and subjected to
Edman degradation on cLC-Procise sequencer (Applied Biosystems).
Aminoglycoside mediated read-through of termination codon.
Wild-type and mutant retrocyclin cDNAs were subcloned into
phCMV-luc-FSR vector to create unrescued RC-101 and rescued
RC-101 C-terminal luciferase fusion constructs, and verified by
sequencing. HOS-CD4-CCR5 cells were cultured in antibiotic free
growth medium (D10) and cotransfected with 0.5 lg of unrescued or
rescued (positive control) RC-101 plasmids along with 0.1 lg of phRL-
CMV vector (transfection control containing renilla luciferase gene)
using Effectene transfection reagent (Qiagen). The next day cells were
treated for 24 h with the appropriate aminoglycoside (40 lg/ml
amikacin or 5 lg/ml gentamicin or 10 lg/ml tobramycin) or D10 for
control cells. Read-through was determined by measuring luciferase
and renilla levels using a dual luciferase assay (Promega).
TZM-bl cells (4,000 cells/well; 96-well plate) were cultured in D10
and treated with vehicle (PBS buffered D10) or peptides RC-101 or
RC-100 (2.5 lg/ml each) as positive control or aminoglycosides as
before for 30 min followed by infection with HIV-1 BaL (p24 of 2 ng/
ml) at 37 8C for 24 h. Subsequently, viral infection was quantified by
measuring luciferase levels using Bright-Glo reagents (Promega).
Cellular metabolism was monitored by measuring reduction the
ability of cellular dehydrogenases to reduce MTT to formazan (R&D
Systems).
TZM-bl cells were cultured on coverslips and treated with PBS
control or 10 lg/ml of tobramycin for 24 h. The coverslips were then
processed for immunofluorescence staining with anti-retrocyclin
(rabbit anti-RC-101 antibody) or preimmune serum as described
above.
For antibody-mediated neutralization experiments, TZM-bl cells
(4,000 cells/well; 96-well plate) were cultured in D10 medium and
treated with vehicle (PBS) or 10 lg/ml of tobramycin for 24 h. The
next day, cells were treated with either rabbit preimmune or anti-
retrocyclin serum diluted 1:10 in D10medium containing tobramy-
cin or RC-100 (2.5 lg/ml). 2 h later the cells were infected with HIV-1
BaL (p24 of 5 ng/ml) at 37 8C for 24 h. Viral infection was quantified
as described above. An MTT assay was performed to confirm that the
treatments were not cytotoxic (unpublished data).
Application of aminoglycosides to organotypic cervicovaginal
tissue model. Cervicovaginal tissues were treated topically with 100
ll of PBS (control; n ¼ 4) or with 10 lg/ml of tobramycin (n ¼ 8) for
24 h. Viability was assessed on control and tobramycin-treated tissue
(n ¼ 1) using MTT assay kit (MatTek Corp.). Cytotoxicity was
measured by quantifying LDH activity in the underlying medium
collected 24 h after treatment with PBS or tobramycin by using
CytoTox96 nonradioactive cytotoxicity assay kit (Promega Corp.).
Supporting Information
Figure S1. Verification of Stable Transfection of Retrocyclin
Constructs
Analysis of the genomic DNA and RNA of transfected HL60 cells
confirms the stable transfection and transcription of rescued
retrocyclin constructs, respectively. (A) PCR on genomic DNA
template from transfected HL60 cells shows a 215-bp fragment
representing retrocyclin cDNA construct and a 890-bp fragment of
native retrocyclin gene in the genomic DNA of A1A3 clones but not
in the VC cells.
(B, C) Correction of the premature termination codon of retrocyclin
cDNA introduces an additional HpyCH4V restriction site in the
middle of an 87-bp cDNA fragment. RNA isolated from HL60 cells
(control, R1R3 clones 1 and 2, and A1A3 clones 1 and 2) was used to
make cDNA. Retrocyclin constructs were amplified by PCR using the
cDNA as template and digested using HpyCH4V restriction enzyme.
Electrophoresis of the digested PCR products shows the expected 87-
bp fragment in control cells (B) and the expected absence of 87-bp
fragment in R1R3 and A1A3 clones (C). All the products were also
verified by DNA sequencing.
Found at doi:10.1371/journal.pbio.1000095.sg001 (1.08 MB TIF).
Table S1. Primers Used for Verification of Retrocyclin Constructs
Found at doi:10.1371/journal.pbio.1000095.st001 (31 KB DOC).
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